Electroacupuncture study for recurring brain cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests if a special type of electroacupuncture can help chemotherapy (paclitaxel) reach the brain more effectively in patients whose high-grade glioma has come back after surgery. The goal is to see if this combination can slow tumor growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of brain cancer called glioblastoma (WHO grade 4) that has come back after surgery.
- You are between 18 and 70 years old.
- You have at least one tumor spot that can be measured on an MRI scan.
- You are able to receive acupuncture and can understand pain and communication.
- You have good enough blood, liver, and kidney function based on recent tests.
- You are not pregnant or breastfeeding, and you have no severe allergies to paclitaxel or similar drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding electroacupuncture (a type of acupuncture with mild electric pulses) to the chemotherapy drug paclitaxel can help people with recurrent high-grade glioma. The goal is to see if the combination works better than paclitaxel alone.
This trial studies giving cetuximab (a targeted antibody) directly into an artery along with repeat radiation to treat certain recurring or treatment-resistant brain tumors. It may help by delivering the drug more directly to tumor areas and testing whether this approach can control the disease after it comes back.
This trial tests an experimental drug, BMS-986504, for people with recurrent glioblastoma (a type of brain cancer). The drug targets a specific genetic change in the tumor. It aims to see if the drug can help shrink or slow the tumor.
This trial tests a combination of two experimental drugs, CTX-009 and CTX-471, for people whose glioblastoma has returned. The goal is to see if these drugs can help control the tumor.
This Phase 2 study tests ERC1671 together with four other medicines to treat recurrent or worsening glioblastoma (a WHO grade IV brain cancer). It aims to slow tumor growth and improve outcomes after the tumor comes back.
This study tests FT536, a new cell-based treatment, for people with a specific type of brain cancer (WHO Grade 4 astrocytoma) that has come back after standard treatment. The trial combines the new therapy with surgery to see if it can help stop the cancer from growing further.
Hear when a new Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.